A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis

D. Galdermans,P. Driesen,F. Bustin,Marc Lambrechts,Koen Deschepper,I. Stappaerts,Dirk Verresen,Annelies Janssens,Paul Germonpre

A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis

2008

D. Galdermans
P. Driesen
F. Bustin
Marc Lambrechts
Koen Deschepper
I. Stappaerts
Dirk Verresen
Annelies Janssens
Paul Germonpre

7594 Background: Several randomized phase III trials in early-stage NSCLC, have shown that Cis-VRB adjuvant chemotherapy improves survival; however, compliance with adjuvant chemotherapy has been p...

Keywords:

non-small cell lung cancer (NSCLC)
Cisplatin/Docetaxel
Adjuvant
Cisplatin/vinorelbine
Interim analysis
Oncology
Internal medicine
Medicine
stage ib
in patient
phase iii trials

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations